Premium
Is interleukin‐1 genotyping useful for the clinical management of patients with atrophic body gastritis?
Author(s) -
LAHNER E.,
CORLETO V. D.,
D’AMBRA G.,
DI GIULIO E.,
DELLE FAVE G.,
ANNIBALE B.
Publication year - 2008
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2007.03581.x
Subject(s) - medicine , atrophic gastritis , gastritis , genotyping , gastroenterology , cancer , genotype , proinflammatory cytokine , atrophy , pathology , helicobacter pylori , inflammation , gene , biology , genetics
Summary Background Atrophic body gastritis patients are at increased risk for gastric cancer. IL‐1B/IL‐1RN polymorphisms have been associated with gastric cancer susceptibility. The relationship between these polymorphisms and the long‐term outcome of atrophic body gastritis patients is not known. Aim To investigate whether the genotyping of IL‐1B‐511/IL‐1RN polymorphisms is useful to characterize atrophic body gastritis patients at increased risk for gastric neoplasms. Methods IL‐1B‐511/IL‐1RN polymorphisms were compared between 110 atrophic body gastritis patients and 110 age‐ and gender‐matched controls, and patients were followed up (median 4.1 years) according to a cohort study design. Results Genotype frequencies of IL‐1B‐511/IL‐1RN were similar between patients and controls. Atrophic body gastritis patients harbouring the wild type of IL‐1B‐511/IL‐1RN polymorphisms were not different from those harbouring the proinflammatory pattern as far as regards gender, age, gastric cancer family history and metaplastic atrophy. Sixteen atrophic body gastritis patients developed a gastric neoplastic lesion at follow‐up: eight were IL‐1B‐511‐T carriers and eight were IL‐1RN‐allele‐2 carriers. Harbouring the proinflammatory genotypes was not significantly associated with developing gastric neoplastic lesions. Conclusions In atrophic body gastritis patients, IL‐1B‐511 and IL‐1RN polymorphisms do not appear to be associated either with specific clinical, biochemical or histological features or with the development of gastric neoplastic lesions at long‐term follow‐up.